Analysts forecast that Orthopediatrics Corp (NASDAQ:KIDS) will announce $19.82 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Orthopediatrics’ earnings, with the lowest sales estimate coming in at $19.65 million and the highest estimate coming in at $20.10 million. Orthopediatrics reported sales of $15.82 million during the same quarter last year, which would suggest a positive year over year growth rate of 25.3%. The firm is expected to issue its next quarterly earnings results on Wednesday, October 30th.

According to Zacks, analysts expect that Orthopediatrics will report full year sales of $71.33 million for the current fiscal year, with estimates ranging from $71.29 million to $71.40 million. For the next fiscal year, analysts forecast that the firm will report sales of $87.46 million, with estimates ranging from $86.59 million to $88.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.05). Orthopediatrics had a negative return on equity of 12.92% and a negative net margin of 15.77%. The business had revenue of $18.20 million during the quarter, compared to analysts’ expectations of $18.44 million. During the same quarter last year, the business posted ($0.21) EPS. The company’s quarterly revenue was up 20.5% compared to the same quarter last year.

A number of research firms have commented on KIDS. Zacks Investment Research lowered Orthopediatrics from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. BidaskClub raised Orthopediatrics from a “sell” rating to a “hold” rating in a report on Saturday, August 17th. BTIG Research reissued a “buy” rating and issued a $44.00 target price on shares of Orthopediatrics in a report on Friday, May 10th. Needham & Company LLC began coverage on Orthopediatrics in a report on Wednesday, June 19th. They issued a “buy” rating and a $53.00 target price for the company. Finally, ValuEngine lowered Orthopediatrics from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $44.25.

KIDS stock traded down $0.55 on Thursday, reaching $32.20. 66,136 shares of the company traded hands, compared to its average volume of 85,495. The company has a market cap of $478.83 million, a P/E ratio of -33.54 and a beta of 0.12. The firm has a fifty day simple moving average of $34.17 and a 200-day simple moving average of $38.68. Orthopediatrics has a one year low of $25.11 and a one year high of $47.82. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.53 and a quick ratio of 1.75.

Several hedge funds have recently bought and sold shares of the company. Aperio Group LLC acquired a new stake in shares of Orthopediatrics in the second quarter worth $39,000. BNP Paribas Arbitrage SA increased its holdings in Orthopediatrics by 83,150.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,665 shares of the company’s stock worth $74,000 after purchasing an additional 1,663 shares in the last quarter. Meadow Creek Investment Management LLC increased its holdings in Orthopediatrics by 125.0% in the second quarter. Meadow Creek Investment Management LLC now owns 2,160 shares of the company’s stock worth $84,000 after purchasing an additional 1,200 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in Orthopediatrics in the fourth quarter worth approximately $93,000. Finally, Bank of Montreal Can increased its holdings in Orthopediatrics by 56.3% in the second quarter. Bank of Montreal Can now owns 2,853 shares of the company’s stock worth $112,000 after purchasing an additional 1,028 shares in the last quarter. 50.52% of the stock is currently owned by institutional investors and hedge funds.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Recommended Story: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.